Serpin B9 controls tumor cell killing by CAR T cells

BACKGROUND: Initial clinical responses with gene engineered chimeric antigen receptor (CAR) T cells in cancer patients are highly encouraging; however, primary resistance and also relapse may prevent durable remission in a substantial part of the patients. One of the underlying causes is the resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimman, Thomas, Slomp, Anne, Martens, Anne, Grabherr, Sarah, Li, Shuang, van Diest, Eline, Meeldijk, Jan, Kuball, Jurgen, Minnema, Monique C, Eldering, Eric, Bovenschen, Niels, Sebestyén, Zsolt, Peperzak, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030924/
https://www.ncbi.nlm.nih.gov/pubmed/36931661
http://dx.doi.org/10.1136/jitc-2022-006364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030924/
https://www.ncbi.nlm.nih.gov/pubmed/36931661
http://dx.doi.org/10.1136/jitc-2022-006364

Ejemplares similares